Zoetis

“we broadened our laboratory footprint across the U.K. and Ireland with the acquisition of Veterinary Pathology Group in November.”

Zoetis acquired Veterinary Pathology Group to expand its reference-laboratory footprint in the UK and Ireland, growing its companion-animal diagnostics reach.

“ProHeart contributions, if any, coming from Merck's product Interceptor Plus Quantum, the last part of that, I would say, no. We do not see any meaningful contributions here.”

Zoetis says rival Merck Animal Health's Interceptor Plus Quantum is not meaningfully denting ProHeart, implying Merck's new parasiticide launch has gained limited traction against Zoetis.

“we are factoring in a full launch of a competitive product in Europe coming in with NUMELVI, which started in the third quarter.”

Zoetis is factoring in the full European launch of competitor derm product NUMELVI (Elanco), which began in Q3, as a competitive dynamic in its dermatology franchise.

“with respect to Zenrelia, both in the U.S. and across international markets, the level of patient share that they are gaining here is certainly in line with our expectations”

Zoetis says the competitive derm product Zenrelia (Elanco's JAK inhibitor) is gaining only limited patient share in line with expectations, indicating contained competitive pressure on Apoquel.

“No word yet in terms of exactly when the Merck approval will be in the U.S. as they have said, they expected approval late this year, early next year.”

Zoetis notes an upcoming Merck dermatology product approval expected in the U.S. late 2025/early 2026, a read-through on Merck Animal Health entering the derm category where Zoetis leads.

“in terms of what we're seeing from Quattro, has been relatively small in terms of anything there, again, given a very high growth in this segment.”

Zoetis characterizes the competitive impact from Quattro, a newly launched rival parasiticide product, as minimal so far given strong overall segment growth.

“Amazon is, now selling some of the online drugs probably, I think it’s just singles right now, but maybe get a broad spectrum.”

Amazon is emerging as an alternative retail channel selling Zoetis pet-health products online, alongside the company's existing retail and home-delivery channels.

“Can you just remind us of your latest expectations for Merck’s entrance into the market?”

Analyst asks Zoetis to characterize the competitive threat from Merck's expected entry into the dermatology (derm) market against Apoquel/Cytopoint.

“can you discuss the new FINTEP-one indication for Simparica Trio versus Elanco’s Credelio and Quattro?”

Analyst frames Elanco's Credelio and Quattro as the direct competitive comparison set for Zoetis's Simparica Trio parasiticide franchise.